Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(100.0%)
4Total
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05621876Completed

Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia

Role: collaborator

NCT00413738Phase 3Completed

Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease

Role: lead

NCT00207805Phase 3Completed

The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma

Role: lead

NCT00207792Phase 3Unknown

Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

Role: lead

NCT00207779Phase 3Completed

Prevention of Catheter-Related Bloodstream Infection in Patients With Haemato-Oncological Disease

Role: lead

All 5 trials loaded